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Abstract 
Background: Two national clinical trial groups, United Kingdom Children’s Cancer and Leukaemia Group (CCLG) and 
the German Paediatric Oncology and Haematology Group (GPOH) together undertook a randomised trial, EICESS-92, 
which addressed chemotherapy options for Ewing’s sarcoma. We sought the causes of unexpected survival differ-
ences between the study groups.
Methods: 647 patients were randomised. Cox regression analyses were used to compare event-free survival (EFS) 
and overall survival (OS) between the two study groups.
Results: 5-year EFS rates were 43% (95% CI 36–50%) and 57% (95% CI 52–62) in the CCLG and GPOH patients, 
respectively; corresponding 5-year OS rates were 52% (95% CI 45–59%) and 66% (95% CI 61–71). CCLG patients were 
less likely to have both surgery and radiotherapy (18 vs. 59%), and more likely to have a single local therapy modal-
ity compared to the GPOH patients (72 vs. 35%). Forty-five percent of GPOH patients had pre-operative radiotherapy 
compared to 3% of CCLG patients. In the CCLG group local recurrence (either with or without metastases) was the 
first event in 22% of patients compared with 7% in the GPOH group. After allowing for the effects of age, metastases, 
primary site, histology and local treatment modality, the risk of an EFS event was 44% greater in the CCLG cohort (95% 
CI 10–89%, p = 0.009), and the risk of dying was 30% greater, but not statistically significant (95% CI 3–74%, p = 0.08).
Conclusions: Unexpected differences in EFS and OS occurred between two patient cohorts recruited within an 
international randomised trial. Failure to select or deliver appropriate local treatment modalities for Ewing’s sarcoma 
may compromise chances of cure.
Trial registration Supported by Deutsche Krebshilfe (Grants No. DKH M43/92/Jü2 and DKH 70-2551 Jü3), and European 
Union Biomedicine and Health Programme (Grants No. BMH1-CT92-1341 and BMH4-983956), and Cancer Research 
United Kingdom. Clinical trial information can be found for the following: NCT0000251
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Background
Collaboration between national clinical study groups 
to run large randomised trials is advantageous, espe-
cially in rare disease settings. It allows rapid accrual of 
larger numbers of patients to provide sufficient power 
for robust analyses. Indeed, joint studies may be the 
only means of effectively answering randomised ques-
tions in rare cancers [1, 2]. EICESS-92, a trial developed 
and completed by the Children’s Cancer and Leukaemia 
Group (CCLG, formerly United Kingdom Children’s 
Cancer Study Group, UKCCSG) and the Cooperative 
Ewing’s Sarcoma Studies (CESS) group of the German 
Paediatric Oncology and Haematology Group (GPOH) 
with associated institutions in Austria, Switzerland and 
the Netherlands, addressed two chemotherapy questions 
in patients with Ewing sarcoma (ES). It remains one of 
the largest randomised studies conducted in this cancer.
The primary aims of the trial were to demonstrate an 
increase in event-free survival (EFS), and decreased 
treatment-related morbidity for patients with standard 
risk disease. The overall results of the trial have been 
reported [3]. However, we found evidence that EFS and 
overall survival (OS) differed between the CCLG and 
GPOH study groups. Although these data have been 
reported in abstract form, this more detailed analysis 
retains relevance and influence on practice [4].
Patients and methods
The trial design of EICESS-92 is outlined in Fig.  1, and 
details are described elsewhere [3]. The study was con-
fined to patients with primary tumours of bone.
Patients with localised tumours of < 100 ml were clas-
sified as standard risk (SR), patients with large localised 
tumours (≥  100  ml), or with metastatic disease, were 
classified as high risk (HR). Patients were randomly 
assigned to one of two treatment arms. SR-patients 
received four VAIA courses (vincristine, doxorubicin, 
ifosfamide, actinomycin D) followed by ten courses of 
Fig. 1 EICESS 92 consort diagram (from original publication Paulussen et al. [3])
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either VAIA or VACA (cyclophosphamide instead of ifos-
famide) whilst HR-patients were randomised to either 
fourteen courses of VAIA or fourteen courses of VAIA 
with etoposide (EVAIA) [3].
Surgery and/or radiotherapy to the primary tumour 
(‘local therapy’) were scheduled to occur after four cycles 
of chemotherapy, at week 12. The choice of local therapy 
was made by clinicians for individual patients. The proto-
col was permissive but indicated that surgery should be 
undertaken whenever possible. Preoperative radiother-
apy (44.8 Gy) was recommended when there was < 50% 
reduction of a soft tissue component, evident on repeat 
imaging after 2 chemotherapy courses. Radiotherapy 
(54.4  Gy) replaced surgery for tumours deemed inoper-
able. Post-operative radiotherapy (54.4  Gy) was recom-
mended after intralesional surgery or marginal surgery 
with poor response (<  90% necrosis). Postoperative 
radiotherapy (44.8 Gy) was to be considered for marginal 
resections with good response (≥ 90% necrosis) or wide 
resections with poor response. Hyperfractionated irra-
diation was recommended in these cases.
In the CESS group, the practice for treating clinical 
teams of routinely seeking advice from clinicians in the 
central trials office is well established including detailed 
guidance about radiotherapy planning [5]. No similar 
process was in place in the UK although the majority 
of patients selected for surgery by local clinicians were 
operated on at four centres only.
Statistical methods
The EICESS database was frozen in March 2007. EFS 
was calculated from the date of randomisation until the 
date of relapse, death or second malignancy, whichever 
occurred first. OS was calculated from the date of ran-
domisation until date of death. Patients alive at last fol-
low-up were censored at date last seen. Kaplan–Meier 
survival curves were examined, and Cox regression mod-
elling was used to investigate differences after adjust-
ing for multiple factors, producing hazard ratios (HR). 
Results are also presented separately for patients with 
only localised disease.
Results
Between 1992 and 1998, 647 patients were randomised: 
210 CCLG and 437 GPOH (CONSORT diagram Fig. 1). 
The median follow-up was 8.5 years.
Patient characteristics
These were largely similar between the trial groups, 
except that CCLG patients tended to have more extrem-
ity tumours (Table 1; 55 vs. 45%), fewer central tumours 
(40 vs. 54%), and fewer with atypical Ewing’s sarcoma (4 
vs. 16%), compared to GPOH patients.
Table 1 Comparison of patient characteristics 
between CCLG and GPOH




N = 210 N = 437
Gender
 Female 84 (40) 177 (40) 0.90
 Male 126 (60) 260 (60)
Age (approx quartiles) (years)
 0–9 34 (16) 94 (22) 0.17
 10–14 74 (35) 123 (28)
 15–19 58 (28) 115 (26)
 20–35 44 (21) 105 (24)
Primary site
 Central axis 84 (40) 236 (54) < 0.001 (0.004)
 Extremity 115 (55) 197 (45)
 Unknown 11 (5) 4 (1)
 Axial skeletal 26 (12) 89 (20)
 Spine 7 (3 30 (7)
 Pelvis 51 (24) 117 (27)
 Limb proximal 61 (29) 103 (23)
 Limb distal 54 (26) 94 (22)
 Unknown 11 (5) 4 (1)
Volume
 < 100 ml 57 (27) 117 (27) 0.48 (0.97)
 ≥ 100 ml 149 (71) 304 (69)
 Unknown 4 (2) 16 (4)
Metastases
 No 150 (71) 329 (75) 0.27 (0.41)
 Yesd 56 (27) 105 (24)
 Unknown 4 (2) 3 (1)
Histology
 Ewing’s sarcoma 140 (67) 261 (60) < 0.001 
(< 0.001) Atypical Ewing’s 8 (4) 70 (16)
 PNET 43 (20) 101 (23)
 Othera 6 (3) 5 (1)
 Unknown 13 (6) 0 (0)
Risk group
 Standard (SR) 53 (25) 102 (23) 0.60
 High (HR) 157 (75) 335 (77)
Trial treatment
 SR-VACA 27 (13) 52 (12) 0.96
 SR-VAIA 26 (12) 50 (11)
 HR-VAIA 76 (36) 164 (38)
 HR-EVAIA 81 (39) 171 (39)
Histological  responsec
 Good 52 (25) [58] 78 (18) [65] < 0.001 [0.33]
 Poor 37 (18) [42] 42 (10) [35]
 No surgery 103 (49) 111 (25)
 NAb 3 (1) 200 (46)
 Unknown 15 (7) 6 (1)
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Where histological response data were available for 
patients who did not receive pre-operative radiotherapy, 
there was no significant difference in the proportion of 
patients from the two study groups with either a good or 
poor histological response (Table 1, p = 0.33).
Chemotherapy and local therapy
There was no evidence of a difference in the delivery of 
chemotherapy between groups. The number of chemo-
therapy cycles received (Table  1) and the median total 
dose for each cytotoxic drug administered per patient 
were similar. A similar proportion completed all 14 
cycles; 62% vs. 58% in the CCLG and GPOH groups, 
respectively (p = 0.30).
Table 2 shows the type of local therapy used in CCLG 
and GPOH patients. Most CCLG patients (72%) had 
a single therapy (surgery alone or radiotherapy alone); 
whilst most GPOH patients had both radiotherapy and 
surgery (59%), which was mainly radiotherapy followed 
by surgery (45%). Only 18% of CCLG patients had both 
radiotherapy and surgery. A similar pattern was seen for 
patients without metastatic disease.
Patient characteristics were examined which might 
influence the selection of local treatment (Table  3). 
Many patients with metastatic disease were treated 
with radiotherapy alone in both trial groups, though 
the percentage was higher in CCLG patients. A sub-
stantial proportion of CCLG patients with central axis 
tumours had radiotherapy alone (62%), while those with 
extremity tumours tended to have surgery alone. CCLG 
patients were more likely to have both radiotherapy 
and surgery if they had extremity tumours compared 
to central axis tumours (23 vs. 11%). A similar pattern 
was seen in GPOH patients, though there was much 
less of a difference in the proportion who had both 
therapies depending on whether they had extremity or 
central axis tumours (64% vs. 54%). While there was 
no evidence of an association between choice of local 
treatment and either tumour volume (p = 0.44) or age 
(p = 0.12) in GPOH patients, there was evidence of this 
in CCLG patients. Those with a volume < 100 ml were 
more likely to have surgery alone (47%), and those with 
a volume ≥100  ml tended to have radiotherapy alone. 
Proportionally more patients with volume ≥100  ml 
received both therapies compared to those with volume 
< 100 ml (21 vs. 10%). In the CCLG group there was a 
clear trend with age; the proportions receiving sin-
gle modality treatment were 94% (age 0–9  years), 75% 
(age 10–14 years), 68% (age 15–19 years) and 59% (age 
20–35 years), indicating that older patients tended to be 
given both therapies.
Overall outcome
Appendix Table  6 shows the distribution of events and 
deaths by trial group. The CCLG cohort had more local 
relapses (with or without metastatic disease) than GPOH; 
22 vs. 7%. Appendix Tables 7, 8 show the distribution of 
events according to local therapy. Figure 2 shows EFS and 
OS according to trial group. Both outcomes were poorer 
in the CCLG patients.
p values including unknown data; the p values in brackets exclude unknown 
data
a Osteosarcoma or soft tissue
b NA not applicable, i.e. patients with early radiotherapy before surgery
c The numbers in square brackets are based only on patients with a good or 
poor response
d The proportions of patients with bone or bone marrow metastases were 
similar: 8% GPOH and 5% CCLG
Table 1 continued




N = 210 N = 437
No. of chemotherapy cycles received
 1–4 18 (8.6) 26 (6.0) 0.32
 5–9 22 (10.5) 62 (14.2)
 10–13 36 (17.10 83 (19.0)
 14 131 (62.4) 254 (58.2)
  Unknown 3 (1.4) 12 (2.8)
Table 2 Comparison of local treatment modality in CCLG 
and GPOH
a p value for the association between type of local treatment and study group. 
The p value is also < 0.001 if ‘none’ or ‘unknown’ are excluded




N = 210 N = 437
Local treatment modality
 Surgery alone 70 (33) 71 (16) < 0.001a
 Radiotherapy alone 81 (39) 85 (19)
 Radiotherapy then surgery 6 (3) 195 (45)
 Surgery then radiotherapy 32 (15) 60 (14)
 None (progressive disease) 18 (9) 7 (2)
 Unknown 3 (1) 19 (4)
Localised disease only
 Surgery alone 59 (39) 63 (19) < 0.001
 Radiotherapy alone 53 (35) 55 (17)
 Radiotherapy then surgery 5 (3) 147 (45)
 Surgery then radiotherapy 24 (16) 47 (14)
 None (progressive disease) 9 (6) 3 (1)
 Unknown 0 14 (4)
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Differences in survival between the trial groups allowing 
for specified factors
The risk of having an event or dying for CCLG patients 
compared to GPOH was examined using Cox regres-
sion modelling. Overall, the chance of having an event 
(relapse, death or second malignancy) was increased by 
42% (HR 1.42, 95% CI 1.13–1.77, p = 0.002) in the CCLG 
group compared to the GPOH group. The CCLG group 
had an increased risk of dying of 45% (HR 1.45, 95% CI 
1.14–1.86, p = 0.003) in comparison to the GPOH group 
(Appendix Table 9). The table also shows that the excess 
risk (42% EFS, and 45% OS) did not materially change, 
even after allowing for several prognostic factors: age, 
metastatic disease status, primary site or histology. The 
association between outcome and study group was very 
similar when only examining patients with non-met-
astatic disease. Combined local treatment seemed to 
have an effect on OS (reducing the excess risk from 45 to 
30%) but not EFS. When several prognostic factors were 
allowed for together, there was still an increased risk 
among CCLG patients: 44% for EFS (HR 1.44, p = 0.009) 
and 30% for OS (HR 1.30, p = 0.08, which was not sta-
tistically significant). We further examined the effect 
separately among patients with localised disease only and 
those with metastatic disease. The EFS and OS hazard 
ratios were: 1.47 (95% CI 1.11–1.96) and 1.52 (95% CI 
1.11–2.07) for those with localised disease only. For those 
with metastatic disease, the HRs for EFS and OS were: 
1.20 (95% CI 0.82–1.74) and 1.22 (95% CI 0.82–1.80) 
based on all patients, and 0.98 (95% CI 0.65–1.48) and 
1.01 (0.66–1.57) based on those who had local therapies.
In an analysis in which only patients that had a local 
recurrence (with or without distant recurrence) were 
counted as an event (all other events censored at the 
time when they occurred), an excess risk was still found 
in CCLG patients compared to GPOH. The hazard ratios 
were: 3.46 (95% CI 2.19–5.47) unadjusted, and 3.47 (95% 
CI 2.00–6.01), allowing for age, primary site, histology 
and local treatment.
Appendix Table  9 also shows hazard ratios for CCLG 
compared to GPOH patients only among those who 
received local treatment. The HRs were 1.22 and 1.28 
for EFS and OS, respectively. These estimates were 
somewhat lower than those in all patients (and only just 
missed statistical significance, due to being based on a 
smaller number of patients), indicating that the differ-
ence between the HRs based on all patients and those 
based only on those who had local treatment is largely 
due to excluding those with progressive disease or miss-
ing data on local therapy. The EFS HR of 1.22 reduced 
Table 3 Association between the choice of local modality treatment and specified patient characteristics
Chi square tests were used to examine the association between each factor and choice of local therapy, excluding those who received no local treatment (‘None’ in 
the table)
CCLG: disease (p = 0.04); primary site (p < 0.001); volume (p = 0.01); age (p = 0.01)
GPOH: disease (p = 0.002); primary site (p < 0.001); volume (p = 0.44); age (p = 0.12)
N total number of patients RT radiotherapy
Number of patients (percentage), excluding missing data
CCLG GPOH
N None RT alone Surgery alone RT and surgery N None RT alone Surgery alone RT and surgery
Disease
 Localised 150 9 (6) 53 (35) 59 (39) 29 (19) 315 3 (1) 55 (17) 63 (20) 194 (62)
 Metastatic 56 9 (16) 27 (48) 11 (20) 9 (16) 101 4 (4) 30 (30) 8 (8) 59 (58)
 Localised extremity disease 91 5 (5) 18 (20) 46 (50) 22 (24) 155 1 (1) 8 (5) 44 (28) 102 (66)
 Localised pelvic disease 31 0 24 (77) 6 (19) 1 (3) 79 1 (1) 27 (36) 7 (9) 39 (53)
Primary site
 Central axis 84 9 (11) 52 (62) 14 (17) 9 (11) 226 4 (2) 73 (32) 22 (10) 127 (56)
 Extremity 115 7 (6) 28 (24) 54 (47) 26 (23) 189 3 (2) 11 (6) 48 (25) 127 (67)
Volume (ml)
 < 100 57 5 (9) 19 (33) 27 (47) 6 (10) 111 3 (3) 26 (23) 16 (14) 66 (59)
 ≥ 100 146 13 (9) 61 (42) 40 (27) 32 (22) 292 4 (1) 54 (18) 52 (18) 182 (62)
Age (years)
 0–9 34 0 10 (29) 22 (65) 2 (6) 92 1 (1) 18 (20) 22 (24) 51 (55)
 10–14 74 5 (7) 32 (43) 24 (32) 13 (18) 118 0 30 (25) 11 (9) 77 (65)
 15–19 56 5 (9) 25 (45) 13 (23) 13 (23) 111 3 (3) 21 (19) 21 (19) 66 (59)
 20–35 43 8 (19) 14 (33) 11 (26) 10 (23) 97 3 (3) 16 (16) 17 (18) 61 (63)
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to 1.14 after allowing for the type of local treatment, i.e. 
it is partly explained by differences in the local therapy 
administered (consistent with Table 2) further indicating 
the influence of local treatments on survival outcomes.
When we examined the effect of different local treat-
ment modalities on outcomes, there was no evidence 
of a difference between CCLG and GPOH patients for 
either EFS or OS among those who received radiother-
apy alone (Table 4). This is not surprising given that the 
proportions with a local relapse (with or without metas-
tases) were not very different: 22% CCLG vs. 16% GPOH 
(Appendix Table 7, 8). The risk of an event or death was 
moderately higher in the CCLG group among patients 
who had surgery alone (excess risk: EFS 31% and OS 50%, 
though neither were statistically significant). However, 
among patients who had both radiotherapy and surgery 
(Table  4), CCLG patients were 67% more likely to have 
an event (p = 0.03) and 65% more likely to die (p = 0.05). 
The adjusted point estimates were similar but were not 
statistically significant (p = 0.07 for both EFS and OS). To 
further consider different numbers of CCLG and GPOH 
patients who received radiotherapy then surgery or 
vice versa, Table 4 shows HRs within in each subgroup: 
there was still evidence of an excess risk among CCLG 
patients. Appendix Table  10 is only based on patients 
without metastatic disease: the conclusions were similar 
to Table 4. Appendix Table 11 is based only on patients 
with metastatic disease: it is difficult to make any reliable 
conclusions because of the smaller patient numbers.
Local treatment and timing of treatment
GPOH patients were more likely to have “early” local 
therapy, i.e. within 12  weeks of starting chemother-
apy, compared to CCLG patients: 43% (176/407) vs. 9% 
(17/180), p  <  0.001. This is consistent with the greater 
use of pre-operative radiotherapy. GPOH patients were 
also less likely to have “late” local therapy, i.e. more than 
15  weeks from start of chemotherapy; 20% (82/407), 
vs. 32% (57/180) p  =  0.004. There was an association 
between clinical outcome and the length of time from the 
start of chemotherapy to the start of local therapy (con-
sidered as a continuous variable). For every increase of 
4 weeks, the risk of an (EFS) event increased by 27% (HR 
1.27, 95% CI 1.05–1.53) among patients who had pre-
operative radiotherapy; 14% (HR 1.14, 95% CI 1.02–1.27) 
among those who had surgery, with or without subse-
quent radiotherapy; and 7% (HR 1.07, 95% CI 0.96–1.19) 
among those who had radiotherapy alone.
Appendix Table  12 examines the influence of type of 
local treatment and its timing (in all patients and only 
those with localised disease). Either factor reduced the 
HRs for EFS and OS to a similar extent. In the multivari-
ate model they were each independent prognostic fac-
tors. However, Table 4 and Appendix Table 10 show that 
when the data were presented by type of treatment, the 
timing had some effect but it still did not largely explain 
the difference between CCLG and GPOH outcomes (sur-
gery with or without radiotherapy).
Localised extremity tumours
Table  5 shows the hazard ratios comparing CCLG with 
GPOH, according to primary site. When 253 patients 
with localised extremity tumours were examined, statis-
tically significant survival differences remained between 
the two study groups. There was a 68% increase in the 
death rate among CCLG patients compared to those in 
GPOH, after allowing for local therapy and other factors 
(Table 5, p = 0.05). The 5-year survival rates were: GPOH 
81% (95% CI 75–87%), and CCLG 62% (95% CI 52–72%). 











UKCCSG 210 87 26
GPOH 437 222 64


















UKCCSG 210 106 38
GPOH 437 261 81









HR 1.42 95% CI (1.13-1.77) 
HR 1.45 95% CI (1.14-1.86) 
Fig. 2 Event-free and overall survival for CCLG and GPOH patients. 
5-year EFS rates: CCLG 43% (95% CI, 36–50%); GPOH 57% (95% CI 
52–62). 5-year OS rates: CCLG 52% (95% CI 45–59%); GPOH 66% (95% 
CI 61–71). 10-year EFS rates: CCLG 41% (95% CI 35–48); GPOH 51% 
(95% CI 46–56). 10-year OS rates: CCLG 49% (95% CI 42–56); GPOH 
60% (95% CI 55–65)
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Table 4 Hazard ratios (CCLG vs. GPOH) according to local treatment modality
Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
Based on data excluding patients with unknown primary site because there were so few
EFS event-free survival; OS overall survival














 EFS 21 105 53 131 93 38
 OS 19 92 41 109 79 30
Unadjusted
 EFS 20 (2.64–161) 0.86 (0.58–1.26) 1.31 (0.76–2.25) 1.67 (1.05–2.66) 2.22 (0.81–6.07) 1.99 (1.05–3.78)
 OS 1.50 (0.56–3.96) 0.95 (0.63–1.44) 1.50 (0.81–2.80) 1.65 (1.00–2.74) 1.96 (0.72–5.37) 2.10 (1.02–4.30)
Adjusted for age, metastatic disease, primary site and histology
 EFS 53 (4.0–477) 0.92 (0.62–1.38) 1.24 (0.70–2.20) 1.82 (1.12–2.94) 2.40 (0.84–6.84) 2.50 (1.24–5.06)
 OS 2.09 (0.64–6.79) 1.06 (0.69–1.63) 1.41 (0.73–2.74) 1.81 (1.07–3.05) 2.21 (0.77–6.35) 2.76 (1.26–6.05)
Adjusted for age, metastatic disease, primary site, histology and time between the start of chemotherapy and starting local treatment
 EFS 0.91 (0.60–1.38) 1.24 (0.70–2.19) 1.61 (0.96–2.70) 1.98 (0.70–5.60) 2.83 (1.30–6.16)
 OS 1.04 (0.67–1.63) 1.43 (0.73–2.78) 1.68 (0.97–2.91) 1.94 (0.68–5.58) 3.39 (1.42–8.06)
Table 5 Hazard ratios (CCLG vs. GPOH) according to primary site and localised disease
Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
Hazard ratios for localised disease were not adjusted for metastatic disease
EFS event-free survival; OS overall survival
No. events Unadjusted Adjusted for age, metastatic disease, 
histology and local treatment
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Central axis
 All (n = 320)
  EFS 177 1.48 (1.08–2.03) 0.02 1.27 (0.89–1.82) 0.19
  OS 154 1.47 (1.05–2.06) 0.03 1.20 (0.82–1.75) 0.36
 Localised (n = 220)
  EFS 102 1.47 (0.97–2.24) 0.07 1.33 (0.82–2.16) 0.24
  OS 87 1.46 (0.93–2.30) 0.10 1.15 (0.69–1.92) 0.58
Extremity
 All (n = 312)
  EFS 140 1.56 (1.12–2.18) 0.009 1.75 (1.18–2.60) 0.005
  OS 112 1.69 (1.17–2.45) 0.006 1.59 (1.02–2.46) 0.04
 Localised (n = 253)
  EFS 99 1.68 (1.13–2.50) 0.01 1.56 (1.00–2.43) 0.05
  OS 75 1.86 (1.18–2.93) 0.007 1.68 (1.00–2.81) 0.05
Pelvic disease
 All (n = 168)
  EFS 100 1.36 (0.90–2.05) 0.14 1.05 (0.65–1.70) 0.84
  OS 90 1.32 (0.85–2.04) 0.21 0.98 (0.60–1.62) 0.94
 Localised (n = 107)
  EFS 56 1.22 (0.69–2.15) 0.51 0.98 (0.51–1.89) 0.96
  OS 51 1.17 (0.64–2.14) 0.61 1.01 (0.51–2.03) 0.97
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There were no differences in the baseline patient char-
acteristics or number of chemotherapy cycles received, 
except a slight excess of atypical ES in GPOH; 15% 
(24/162) vs. 5% (5/91) in CCLG. For patients with local-
ised extremity tumours, combined modality treatment 
was used more frequently in GPOH patients than CCLG 
patients (66% vs. 24%) whereas a greater proportion of 
CCLG patients were treated with radiotherapy alone 
(20% vs. 5%). More CCLG patients had a local recur-
rence, with or without metastatic disease (16% vs. 3%).
Central axis and pelvic tumours
Among patients with central axis tumours, the HRs for 
both EFS and OS reduced after allowing for several fac-
tors, and most of the reduction was due to adjusting for 
local treatment, indicating that this does have a role. A 
more pronounced reduction was seen for patients with 
pelvic disease (HRs: EFS 1.05, OS 0.98). Patients with 
localised pelvic tumours had a similar survival whether 
treated in the CCLG or GPOH: the 5-year OS rates were 
52 and 56%, respectively (p = 0.65), and the adjusted OS 
HR was 1.01, 95% CI 0.51–2.03 (Table 5), allowing for the 
different local treatment modalities used between the 
two cohorts. Radiotherapy alone was the local treatment 
modality used in 77% (24/31) CCLG patients compared 
to 34% (27/79) GPOH patients. Surgery combined with 
radiotherapy was only used for 3% of CCLG patients 
(1/31) compared to 49% of GPOH patients (39/79). A 
survival advantage seemed evident for patients with 
localised pelvic tumours selected for surgery, compared 
to those who had radiotherapy alone (hazard ratio 0.50, 
95% CI 0.28–0.88, p = 0.016).
Discussion
The EICESS-92 clinical trial revealed unexpected dif-
ferences in survival between cohorts of ES patients 
from two countries. Differences in mortality from can-
cer between countries are well documented in Europe, 
especially for common cancers [6, 7]. These differences 
in outcome have also been reported for rare cancers [8, 
9]. Survival in the UK is lower for some cancers than in 
other Western European and Nordic countries. Expla-
nations for these differences may include: registry data 
being unrepresentative or containing artefact; differences 
in population health or use of health resources; differ-
ences in stage of cancer at diagnosis and variable access 
to optimal treatment or expertise [10]. Within EURO-
CARE 3, which examined registry data for 20 European 
countries, 5-year survival from ES ranged from 31 to 86% 
for the period 1990–1994 [11]. The EUROCARE-5 study 
investigated whether survival differences among Euro-
pean countries had changed further from 1999 to 2007 
and found persisting inequalities both for children and 
adolescents and young adults [12, 13]. The main influ-
ences on continued survival disparity are attributable to 
lack of health-care resources and access to modern treat-
ments, lack of specialised centres with multidisciplinary 
teams, delayed diagnosis and treatment and poor man-
agement of treatment, and drug toxicity. However, this 
is unlikely to fully account for the wide range in survival 
from ES reported here.
Given that all patients were treated according to a 
common protocol, the substantial survival differences 
between national study groups in this randomised trial 
are striking. Survival for the entire group of 647 patients 
exceeded 60% but this disguises the 14% inferior 5  year 
survival of the cohort of patients recruited through 
the CCLG. The inferior outcome was not obviously 
accounted for by differences in baseline characteristics, 
delivery of chemotherapy or follow up. Differences were 
found in management of the primary tumour and in the 
rates of local recurrence associated with different treat-
ment modalities. We believe that this evidence provides 
support that variations in local therapy influence survival.
It is possible that inherent differences in health care 
delivery systems between the two study groups may have 
contributed to survival differences. No differences were 
found in the tumour volume and the frequency of pres-
entation with metastases between the two study groups, 
factors which might indicate systematic delays in diagno-
sis in one study group compared to the other. Likewise, 
there was no indication of a systematic difference in the 
way chemotherapy was delivered.
Approaches to local tumour control were clearly differ-
ent between the two groups, including the timing of local 
treatments, but they did not explain all of the difference, 
particularly when patients had surgery. Primary tumour 
control in ES can be achieved with surgery, radiotherapy 
or a combination of both. The choice is based on balanc-
ing the differing morbidities of the two modalities for 
each individual patient. The optimal approach for local 
control remains a topic of debate. The relative merits of 
surgery and radiotherapy have been debated but conclu-
sions are often obscured by patient selection which biases 
comparison [5, 14–17]. Tumours that are inoperable and 
thus treated by radiotherapy alone are often associated 
with other adverse features such as large volume [18–21]. 
The greater incidence of local relapse in CCLG patients 
indicates that both selection of patients for, and delivery 
of, surgery and radiotherapy may have been sub-optimal.
While not specific to Ewing sarcoma, there is a gen-
eral consensus on the relevance of centralization to high 
volume centres and networks for sarcoma, especially for 
diagnosis and surgery [22, 23]. The degree of centralisa-
tion and the process of decision-making about local ther-
apy differed between the two study groups in EICESS-92. 
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Ideally, the optimal local treatment for an individual 
patient should be decided through consideration of 
patient characteristics, the potential benefit and harm 
of the treatment options, and patient preference. In the 
CESS group, treatment took place in three hundred or 
more centres, most of which treat relatively few patients. 
However, each centre was familiar with accessing special-
ist guidance from the trial headquarters. This extended 
to a centralised system of advice for local therapy plan-
ning [5]. A consequence is likely to have been consider-
able consistency of local treatment approach within the 
majority of the GPOH cohort. In contrast, although sur-
gery for bone sarcomas took place mainly in four centres 
in the UK, advice about local tumour management was 
only sought on an ad hoc basis and there was no similar 
system for any degree of central treatment planning.
The EICESS-92 trial is an example of how collaboration 
between national clinical study groups is required to run 
large randomised trials with sufficient power for robust 
analyses in rare cancers. It is acknowledged that the work 
has been delayed in its publication but it has been revis-
ited to coincide with a strong current focus and drive for 
international consensus on the role of surgery and radio-
therapy in ES.
The low rates of local recurrence evident with patients 
undergoing combined modality treatment and the 
enhanced survival for a cohort of patients, more of whom 
underwent surgical resection and received radiother-
apy, indicates that clinicians should always consider this 
option. Nevertheless, this must be balanced against the 
additional late effects, including second malignancies, 
which are associated with the use of radiotherapy in ES.
Conclusion
In summary, unexpected differences in survival between 
cohorts of patients within the same randomised trial have 
been identified and are national in origin. It appears that 
less aggressive methods of local control have resulted in 
a higher rate of local recurrence and this was associated 
with a higher risk of metastatic disease and subsequent 
death. These data reinforce the importance of careful 
planning of treatment for local tumour control in ES and 
that radiotherapy alone should be discouraged when sur-
gical resection can be undertaken. International clinical 
trials may offer opportunities to explore the impact of 
different treatment approaches. As a consequence of the 
results from this trial, the UK has initiated a system for 
centralised national review and guidance on local treat-
ment decision making for ES. This system is currently 
undergoing evaluation.
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Table 6 Number of patients and events according to trial group
As a percentage of the number of patients from either CCLG or GPOH






First events (total) 119 (57) 204 (47) 323
 Death-treatment related 1 (0.5) 3 (1) 4
   Disease progression 3 (1) 12 (3) 15
  Unknown cause 3 (1) 1 (0.2) 3
 Distant metastases 66 (31) 148 (34) 214
[Distant metastases in those with metastatic disease at baseline] [25 (12%)] [57 (13%)] [82]
 Local relapse 29 (14) 13 (3) 42
 Local and distant relapse 16 (8) 18 (4) 34
 Relapse (unspecified site) 0 4 (1) 4
 Second malignancy 2 (1) 5 (1) 7
All deaths 105 (50) 168 (38) 273
Table 7 Distribution of first events by treatment modality: CCLG patients
RT radiotherapy













No event 41 (59) 31 (38) 2 (33) 14 (44) 0 2 (67) 90
Local recurrence 5 (7.1) 12 (15) 1 (17) 1 (3.1) 10 (56) 0 29
Distant recurrence 18 (26) 28 (35) 1 (17) 13 (41) 5 (28) 1 (33) 66
Local and distant 3 (4.3) 6 (7.4) 2 (33) 3 (9.4) 2 (11) 0 13
Relapse-unspecified 0 0 0 0 0 0 0
Second malignancy 1 (1.4) 1 (1.2) 0 0 0 0 2
Death—no relapse 2 (2.9) 3 (3.7) 0 1 (3.1) 1 (5.6) 0 7
All deaths 24 (34) 45 (56) 4 (67) 15 (47) 16 (89) 1 (33) 105
Table 8 Distribution of first events by treatment modality: GPOH patients
To one decimal place if < 10%
RT radiotherapy
Local treatment modality, N (%) Total
Surgery alone











No event 46 (65) 30 (35) 106 (54) 38 (63) 1 (14) 12 (63) 233
Local recurrence 3 (4.2) 3 (3.5) 3 (1.5) 4 (6.7) 0 0 13
Distant recurrence 19 (27) 36 (42) 71 (36) 16 (27) 2 (29) 4 (21) 148
Local and distant 2 (2.8) 10 (12) 4 (2.0) 1 (1.7) 0 1 (5.3) 18
Relapse-unspecified 0 1 (1.2) 2 (1.0) 0 0 1 (5.3) 4
Second malignancy 1 (1.4) 2 (2.4) 2 (1.0) 0 0 0 5
Death—no relapse 0 3 (3.5) 7 (3.6) 1 (1.7) 4 (57) 1 (5.3) 16
All deaths 18 (25) 47 (55) 75 (38) 17 (28) 6 (86) 5 (26) 158
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Table 9 Hazard ratios for comparing CCLG and GPOH patients
Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
EFS event-free survival; OS overall survival
a Using Cox regression modelling (age as a continuous variable). Missing data for the other variables were included as a separate category, but excluding these from 
the analyses did not materially change the hazard ratio estimates in the table
b Includes categories for no local therapy and missing data
c Surgery alone, radiotherapy alone, surgery then radiotherapy, radiotherapy then surgery
EFS OS
HR (95% CI) p value HR (95% CI) p value
All patients
 Unadjusted 1.42 (1.13–1.77) 0.002 1.45 (1.14–1.86) 0.003
 Unadjusted HR, in localised disease only 1.47 (1.11–1.96) 0.007 1.52 (1.11–2.07) 0.009
 Adjusted for risk group and trial treatment 1.43 (1.14–1.79) 0.002 1.49 (1.17–1.91) 0.001
Adjusted for each of the following factors  separatelya
 Age 1.45 (1.15–1.81) 0.001 1.47 (1.15–1.88) 0.002
 Metastatic disease 1.38 (1.10–1.73) 0.005 1.42 (1.11–1.81) 0.005
 Primary site 1.48 (1.18–1.86) <0.001 1.52 (1.19–1.95) 0.001
 Histology 1.41 (1.12–1.77) 0.004 1.44 (1.12–1.85) 0.004
 Local treatment  modalityb 1.45 (1.12–1.89) 0.006 1.30 (0.98–1.72) 0.07
 Adjusted for age, metastatic disease, primary site, histology and local  treatmenta 1.44 (1.10–1.89) 0.009 1.30 (0.97–1.74) 0.08
 Adjusted HR, in localised disease only 1.48 (1.05–2.09) 0.026 1.29 (0.88–1.89) 0.19
Only patients who had local therapy; excluding progressive disease (n = 25) and where it was not known whether local therapy was given or not 
n = 22)
 Unadjusted 1.22 (0.96–1.55) 0.11 1.28 (0.99–1.67) 0.06
 Adjusted for type of local  treatmentc 1.14 (0.87–1.51) 0.34 1.25 (0.92–1.68) 0.15
 Adjusted for time between the start of chemotherapy and starting local treatment 1.12 (0.87–1.44) 0.37 1.18 (0.90–1.55) 0.22
 Adjusted for age, metastatic disease, primary site, histology, local treatment, and time between 
the start of chemotherapy and starting local treatment
1.13 (0.84–1.50) 0.42 1.25 (0.91–1.71) 0.17
Table 10 Hazard ratios (CCLG vs. GPOH) according to local treatment modality, among patients with localised disease 
only
Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
Based on data excluding patients with unknown primary site because there were so few
EFS event-free survival; OS overall survival












 EFS 62 42 83 61 22
 OS 53 33 66 49 17
Unadjusted
 EFS 0.89 (0.54–1.46) 1.44 (0.78–2.64) 1.66 (0.94–2.96) 2.44 (0.76–7.81) 2.36 (1.02–5.45)
 OS 0.99 (0.56–1.64) 1.74 (0.86–3.51) 1.60 (0.84–3.06) 2.70 (0.84–8.73) 2.03 (0.78–5.28)
Adjusted for age, primary site and histology
 EFS 0.98 (0.58–1.66) 1.51 (0.78–2.94) 1.65 (0.91–2.99) 2.39 (0.71–8.05) 2.12 (0.83–5.40)
 OS 1.10 (0.62–1.95) 1.94 (0.89–4.25) 1.50 (0.77–2.93) 3.10 (0.90–10.70) 1.74 (0.60–5.08)
Adjusted for age, primary site, histology and time between the start of chemotherapy and starting local treatment
 EFS 0.95 (0.54–1.67) 1.48 (0.76–2.89) 1.48 (0.81–2.69) 1.69 (0.50–5.68) 2.10 (0.82–5.41)
 OS 1.03 (0.55–1.90) 1.92 (0.87–4.24) 1.39 (0.71–2.74) 2.49 (0.72–8.58) 1.74 (0.59–5.10)
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Table 11 Hazard ratios (CCLG vs. GPOH) according to local treatment modality, among patients with metastatic disease 
only
Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
Based on data excluding patients with unknown primary site because there were so few
EFS event-free survival; OS overall survival
Local treatment modality
Radiotherapy (RT) alone






 EFS 43 11 48
 OS 39 8 43
Unadjusted
 EFS 0.79 (0.43–1.44) 0.79 (0.24–2.61) 2.01 (0.89–4.54)
 OS 0.92 (0.49–1.74) 0.71 (0.18–2.85) 1.98 (0.88–4.47)
Adjusted for age, primary site, histology and time between the start of chemotherapy and starting local treatment
 EFS 0.81 (0.44–1.67) Too few patients to allow for other factors reliably 2.51 (0.89–7.06)
 OS 1.01 (0.50–2.01) 2.54 (0.90–7.20)
Table 12 Hazard ratios for comparing CCLG and GPOH patients, after examining local treatment and time to local treat-
ment
Type of local treatment and time to local treatment seem to be independent factors. In the Cox regression which contains both of them, the p values for each variable 
are: All patients EFS: local treatment (p < 0.0001); time to local treatment (p < 0.001)
All patients OS: local treatment (p < 0.0001); time to local treatment (p < 0.001)
Patients with localised disease only, EFS: local treatment (p = 0.002); time to local treatment (p = 0.002)
Patients with localised disease only OS: local treatment (p = 0.002; time to local treatment (p = 0.004)
a Surgery alone, radiotherapy alone, surgery then radiotherapy, radiotherapy then surgery
EFS OS
HR (95% CI) p value HR (95% CI) p value
All patients
 Unadjusted 1.22 (0.96–1.56) 0.10 1.29 (0.99–1.68) 0.055
 Adjusted for local  treatmenta 1.14 (0.87–1.51) 0.34 1.25 (0.93–1.68) 0.15
 Adjusted for between the start of chemotherapy and starting local treatment 1.13 (0.88–1.45) 0.34 1.19 (0.91–1.56) 0.20
 Adjusted for both local treatment and timing 1.11 (0.84–1.47) 0.46 1.21 (0.90–1.65) 0.21
Localised disease only
 Unadjusted 1.31 (0.97–1.76) 0.08 1.39 (1.00–1.93) 0.048
 Adjusted for local  treatmenta 1.22 (0.87–1.72) 0.25 1.30 (0.89–1.90) 0.17
 Adjusted for between the start of chemotherapy and starting local treatment 1.18 (0.87–1.60) 0.30 1.24 (0.88–1.74) 0.21
 Adjusted for local treatment and the time between the start of chemotherapy and starting 
local treatment
1.14 (0.81–1.62) 0.45 1.20 (0.82–1.77) 0.35
Metastatic disease only
 Unadjusted 0.98 (0.65–1.48) 0.93 1.01 (0.66–1.57) 0.94
 Adjusted for local  treatmenta 0.98 (0.61–1.56) 0.93 1.11 (0.68–1.81) 0.69
 Adjusted for between the start of chemotherapy and starting local treatment 0.95 (0.62–1.45) 0.81 1.00 (0.64–1.57) 0.98
 Adjusted for both local treatment and timing 0.99 (0.61–1.60) 0.97 1.14 (0.69–1.89) 0.60
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